Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13923709 | 0.78 | CA12 (0.43) | ALDH1A1SMN1; SMN2L3MBTL1KDM4EHPGD | |
| SCHEMBL3965642 | 0.77 | MAPT (0.49) | L3MBTL1ROCK1MAPTMEN1KMT2A | |
| SCHEMBL29951155 | 0.77 | MAPT (0.49) | L3MBTL1ROCK1MAPTMEN1KMT2A | |
| SCHEMBL29953078 | 0.76 | KDM4E (0.54) | ALDH1A1KDM4EHPGDHSD17B10MAPT | |
| SCHEMBL29951367 | 0.76 | RXFP1 (0.47) | KDM4EMAPTMEN1KMT2A | |
| SCHEMBL5071871 | 0.75 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2L3MBTL1KDM4EHPGD | |
| SCHEMBL19539121 | 0.75 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2L3MBTL1KDM4EHPGD | |
| SCHEMBL16023576 | 0.74 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2L3MBTL1KDM4EHPGD | |
| SCHEMBL7971117 | 0.73 | MAOA (0.58) | ALDH1A1SMN1; SMN2L3MBTL1KDM4EHPGD | |
| SCHEMBL29187769 | 0.73 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2L3MBTL1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. | 2016-08-11 | — | — | US | disclosed |
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. | 2016-08-11 | — | — | US | disclosed |
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. | 2016-08-11 | — | — | US | disclosed |
| US-9370515-B2 | Mixed lineage kinase inhibitors and method of treatments | Califia Bio, Inc. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9370515-B2 | Mixed lineage kinase inhibitors and method of treatments | Califia Bio, Inc. (US) | 2016-06-21 | — | — | US | disclosed |
| EP-2964230-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. (US) | 2016-01-13 | — | — | EP | disclosed |
| WO-2014138692-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20140256733-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256733-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | MAP3K2, MAP3K1, MAP3K20 | ALDH1A1 3770/4885SMN1; SMN2 2679/4885L3MBTL1 2389/4885 |
| US-20140256733-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | MAP3K2, MAP3K1, MAP3K20 | ALDH1A1 3770/4885SMN1; SMN2 2679/4885L3MBTL1 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.